1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Gonzalez, CA, Pera, G, Agudo, A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107: 629–634.
Google Scholar | Crossref | Medline3. Lee, YC, Chiang, TH, Chou, CK, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150: 1113–1124.e5.
Google Scholar4. Yang, P, Zhou, Y, Chen, B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45: 2867–2873.
Google Scholar | Crossref | Medline5. Song, H, Ekheden, IG, Zheng, Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015; 351: h3867.
Google Scholar | Medline6. Karimi, P, Islami, F, Anandasabapathy, S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014; 23: 700–713.
Google Scholar | Crossref | Medline7. Forgacs, I, Loganayagam, A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2–3.
Google Scholar | Crossref | Medline8. Ahn, JS, Eom, CS, Jeon, CY, et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol 2013; 19: 2560–2568.
Google Scholar | Crossref | Medline9. Tran-Duy, A, Spaetgens, B, Hoes, AW, et al. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1706–1719.e5.
Google Scholar | Crossref | Medline10. Jiang, K, Jiang, X, Wen, Y, et al. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: a systematic analysis. J Gastroenterol Hepatol 2019; 34: 1898–1905.
Google Scholar | Crossref | Medline11. Wan, QY, Wu, XT, Li, N, et al. Long-term proton pump inhibitors use and risk of gastric cancer: a meta-analysis of 926 386 participants. Gut 2019; 68: 762–764.
Google Scholar | Crossref | Medline12. Lin, J-L, Lin, J-X, Zheng, C-H, et al. Long-term proton pump inhibitor use and the incidence of gastric cancer: a systematic review and meta-analysis. J Gastric Surg 2020; 2: 1–11.
Google Scholar | Crossref13. Song, HJ, Jeon, N, Squires, P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020; 76: 1437–1456.
Google Scholar | Crossref | Medline14. Brusselaers, N, Lagergren, J, Engstrand, L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol 2019; 62: 101585.
Google Scholar | Crossref | Medline15. Lai, SW, Lai, HC, Lin, CL, et al. Proton pump inhibitors and risk of gastric cancer in a case-control study. Gut 2019; 68: 765–767.
Google Scholar | Crossref | Medline16. Lee, JK, Merchant, SA, Schneider, JL, et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol 2020; 115: 706–715.
Google Scholar | Crossref | Medline17. Liu, P, McMenamin, ÚC, Johnston, BT, et al. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer 2020; 123: 307–315.
Google Scholar | Crossref | Medline18. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
Google Scholar | Crossref19. Wennerstrom, ECM, Simonsen, J, Camargo, MC, et al. Acid-suppressing therapies and subsite-specific risk of stomach cancer. Br J Cancer 2017; 116: 1234–1238.
Google Scholar | Crossref | Medline20. Sterne, JA, Hernán, MA, Reeves, BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.
Google Scholar21. Sterne, JACHM, McAleenan, A, Reeves, BC, et al. Chapter 25: assessing risk of bias in a non-randomized study. In: Cochrane handbook for systematic reviews of interventions, 2021, p. 6.2, https://training.cochrane.org/handbook/current/chapter-25
Google Scholar22. Balduzzi, S, Rücker, G, Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22: 153–160.
Google Scholar | Crossref | Medline23. Hartung, JKG . A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 2001; 20: 3875–3889.
Google Scholar | Crossref | Medline | ISI24. Hartung, J. An alternative method for meta-analysis. Biom J 1999; 46: 901–916.
Google Scholar | Crossref25. Sidik, KJJ . A simple confidence interval for meta-analysis. Stat Med 2002; 21: 3153–3159.
Google Scholar | Crossref | Medline | ISI26. Sidik, KJJ . On constructing confidence intervals for a standardized mean difference in meta-analysis. Commun Stat Simul Comput 2003; 32: 1191–1203.
Google Scholar | Crossref | ISI27. Chien, LN, Huang, YJ, Shao, YH, et al. Proton pump inhibitors and risk of periampullary cancers: a nested case-control study. Int J Cancer 2016; 138: 1401–1409.
Google Scholar | Crossref | Medline28. Poulsen, AH, Christensen, S, McLaughlin, JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100: 1503–1507.
Google Scholar | Crossref | Medline | ISI29. Brusselaers, N, Wahlin, K, Engstrand, L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017; 7: e017739.
Google Scholar | Crossref30. Niikura, R, Hayakawa, Y, Hirata, Y, et al. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut 2017; 22: 22.
Google Scholar31. Cheung, KS, Chan, EW, Wong, AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28–35.
Google Scholar | Crossref | Medline32. Egger, M, Davey Smith, G, Schneider, M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
Google Scholar | Crossref | Medline33. García Rodríguez, LA, Lagergren, J, Lindblad, M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55: 1538–1544.
Google Scholar | Crossref | Medline34. Tamim, H, Duranceau, A, Chen, LQ, et al. Association between use of acid-suppressive drugs and risk of gastric cancer. Drug Saf 2008; 31: 675–684.
Google Scholar | Crossref | Medline35. Peng, YC, Huang, LR, Lin, CL, et al. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut 2019; 68: 374–376.
Google Scholar | Crossref | Medline36. Lee, JK, Merchant, SA, Schneider, JL, et al. Long-term proton pump inhibitor use and risk of gastrointestinal cancers. Gastroenterology 2019; 156: 163.
Google Scholar | Crossref37. Crane, SJ, Locke, GR, Harmsen, WS, et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 2007; 102: 1596–1602.
Google Scholar | Crossref | Medline38. DeMeester, SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006; 13: 12–30.
Google Scholar | Crossref | Medline39. Imamura, Y, Watanabe, M, Oki, E, et al. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021; 5: 46–59.
Google Scholar | Crossref | Medline40. Carr, JS, Zafar, SF, Saba, N, et al. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer 2013; 44: 143–151.
Google Scholar | Crossref | Medline41. Olkin, I, Dahabreh, IJ, Trikalinos, TA. GOSH: a graphical display of study heterogeneity. Res Synth Methods 2012; 3: 214–223.
Google Scholar | Crossref | Medline42. Suissa, S, Suissa, A. Proton-pump inhibitors and increased gastric cancer risk: time-related biases. Gut 2018; 67: 2228–2229.
Google Scholar | Crossref | Medline43. Beckh, K, Koop, H, Lankisch, PG, et al. Gastroenterologie compact. Stuttgart; New York: Georg Thieme Verlag, 2013, https://www.thieme-connect.de/products/ebooks/book/10.1055/b-002-57172
Google Scholar44. Waldum, HL, Rehfeld, JF. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia. Scand J Gastroenterol 2019; 54: 1118–1123.
Google Scholar | Crossref | Medline45. Lundell, L, Vieth, M, Gibson, F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649–663.
Google Scholar | Crossref | Medline46. Moayyedi, P, Veldhuyzen van Zanten, SJO, Hookey, L, et al. Proton pump inhibitors and gastric cancer: association is not causation. Gut 2019; 68: 1529–1530.
Google Scholar | Crossref | Medline47. Simin, J, Liu, Q, Fornes, R, et al. Safety of proton pump inhibitors questioned based on a large randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2020; 158: 1172–1173.
Google Scholar | Crossref | Medline48. Brusselaers, N, Lagergren, J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open 2018; 8: e021869.
Google Scholar | Crossref49. Cheung, KS, Leung, WK. Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication. Oncotarget 2018; 9: 36891–36893.
Google Scholar | Crossref | Medline50. Hernán, MA, Robins, JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016; 183: 758–764.
Google Scholar | Crossref | Medline51. Xie, Y, Bowe, B, Yan, Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019; 365: l1580.
Google Scholar | Medline